ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)

Research To Practice | Oncology Videos · Nov 3, 2025 · 42m

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)

Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)

Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)

Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)

Case: Patient with…